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132 Poster Session-IIeosinophils in bone marrow, gut and peripheral blood were ana-
lysed by using SPSS.
Results: The incidence of acute GvHD was 51% (36% grade 1,
27% grade 2, 15% grade 3 and 22% grade 4 out of it). One organ
aGVHD was diagnosed in 42 (skin n 5 36, gut n 5 4, liver n 5 2),
two-organ aGvHD in 10 and tree-organ aGvHD in 7 patients.
The density of bone marrow eosinophils was increased after RIC-
SCT in comparison to before it (6% vs 3.4%, p\0.001, respectively).
Bone marrow eosinophilia after RIC-SCT was found in 66% of pa-
tients with aGvHD and was a significant predictive factor (p\0.03)
for developing aGvHD. However, eosinophil density did not corre-
lated with aGvHD severity. Peripheral blood eosinophilia was not
predictive for developing aGvHD. Intestinal eosinophils were found
in 15 of 20 patients with clinical signs of gut GvHD, which has been
consequently histologically proven in 13 patients (87%, p\0.02).
The degranulation of eosinophils, determined by using anti-MBP
was present in all patients with gut aGvHD.
Conclusions: Both gastrointestinal tract and bone marrow tissue
eosinophilia after RIC-SCT predict aGvHD. In addition, gut eosin-
ophil density and degranulation were increased in patients with
higher grades of aGvHD thus indicating their role as a biological
marker of GvHD. To our knowledge this is the first study showing
that tissue eosinophil density might be a predictive marker for
aGvHD after RIC-SCT.368
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Allogeneic transplantation is uniquely curative for some patients
with hematologic malignancies. However, morbidity and mortality
due to graft versus host disease remain substantial. Persistence of
host dendritic cells (DCs) in the early post transplant period plays
a role in the activation of alloreactive lymphocytes and the risk of
GVHD. A focus of research involves the manipulation of DC re-
covery post-transplant to minimize activation of alloreactive lym-
phocytes while preserving the graft versus disease effect. Vitamin
D is a hormone involved in bone metabolism. More recently, vi-
tamin D has been shown to have immunomodulatory effects. We
evaluated the effect of vitamin D on the phenotypic and functional
characteristics of DC and T cell populations. Peripheral blood
mononuclear cells were isolated from leukopaks obtained from
normal donors. DCs were generated by culturing the monocyte
enriched adherent fraction with GM-CSF and IL-4 for 5 days,
followed by TNFa for 48 hours. DCs were generated in the
presence and absence of 10nM of 1,25 hydroxyvitamin D. Mean
expression of the costimulatory molecule CD80 and the matura-
tion marker CD83 decreased from 60% to 37% and 53% to
27% respectively in the presence of vitamin D (N 5 3). To assess
the effect of vitamin D on the functional potency of DCs as anti-
gen presenting cells, the capacity of DCs to stimulate allogeneic
T cell proliferation in the presence of vitamin D was determined.
Mature DCs were cultured with allogeneic T cells at a ratio of
1:10. After 5 days, cocultures were pulsed with tritiated thymidine
overnight. The addition of vitamin D resulted in a blunted T cell
proliferative response, with mean SI that decreased from 13 to 5
(n 5 10). Similarly, the addition of vitamin D to a coculture of
DCs and autologous T cells resulted in a 50% reduction in the
T cell proliferative response to tetanus toxoid, a recall antigen.
In addition, T cells stimulated by allogeneic DCs in the presence
of vitamin D were polarized to secrete Th2 cytokines. The pres-
ence of vitamin D did not induce FOXP3 expressing regulatory
T cell populations. These data suggest that exposure to vitamin
D exerts a tolerizing influence on T cells mediated by its impact
on antigen presenting cells. Vitamin D may therefore have a role
in the prevention and treatment of graft versus host disease.
A clinical trial evaluating the use of vitamin D in the early post-
transplant period for the prevention of GVHD is planned.369
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Majority of the reported studies comparing allogeneic versus au-
tologous SCT in patients with FL have short follow-up (median 5
or\5-yrs). Patients with histologically confirmed FL (n 5 117) un-
dergoing SCT between 1985 and 2007 were eligible for this study.
Patient characteristics including age, stage, LDH, number of prior
therapies, remission status at SCT [CR, PR, untreated relapse
(REL), refractory (REF)], and transplant characteristics were re-
corded. The median age was 49 years (range 23–71). 36 patients un-
derwent allogeneic SCT (including 10 patients receiving reduced
intensity conditioning), while 81 patients underwent autologous
SCT.Themedian number of prior treatments for autologous and al-
logeneic SCT groups were 2 (range 1–5) and 3 (range 1–7) respec-
tively. Median follow-up is 7-years. 5-year OS following
autologous SCT for patients in CR1/PR1, CR.1/PR.1 and re-
lapsed or refractory disease was 79%, 71% and 53% respectively.
The respective OS for allogeneic SCTwas 51%, 75%, and 49%. Re-
lapse rates were lower following allogeneic SCT versus autologous
SCT at 27%versus 55% respectively. 5 year progression free survival
(PFS) was higher following allogeneic SCT at 46% versus 38%.
Higher non-relapse mortality (NRM) with allogeneic SCT (25%
versus 11%) resulted in a 5 year OS favoring autologous SCT
(67% versus 57%). With prolonged follow-up a plateau was seen
in allogeneic SCT curve at around 3-yrs, while autologous SCT pa-
tients continued to experience events. Hence the estimates of 10-yr
OS for allogeneic SCT patients was 57% (unchanged from 5-yr
OS), compared to 48% for autologous SCT. Our study shows that
although the early results of allogeneic SCT (mostly withmyeloabla-
tive conditioning) are negatively impacted with associated high
NRM, it produces durable remissions, with eventual appearance of
trends of improved survival with prolonged follow-up.370
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Children undergoing AlloSCT exhibit higherMMF dose require-
ments and significant interpatient variability in mycophenolic acid
(MPA) PK (Jacobson P et al, Ped 2008). The objective of this study
is to evaluate effects of age and conditioning intensity on the PK
of MMF in pediatric AlloSCT recipients. From 1/04-5/08 we en-
rolled 38 pts: med age 8 yrs (0.33–16); M:F 5 20:18; 22/16 malig-
nant/non; 17/21 myeloablative (MA)/non-ablative (NMA); 16/22
related/unrelated. Cohort 1 (\6 yrs) n 5 14; 2 (6–12 yrs) n 5 10;
3 (12–16 yrs) n 5 12. GVHD prophylaxis: tacrolimus Day –1 (5–
20 ng/mL) and MMF 900 mg/m2 IV Q6H starting on Day 11,
then converted to PO (same dose) after Day 114. MPA serum sam-
ples were drawn on Days11,17,114 (IV phase) and twice between
Day 145-1100 (PO phase) at hour 0, 0.5, 1, 2, 3, 4, 6 post-dose.
MPA plasma concentrations were determined by reverse-phase
HPLC and LC/MS/MS. Non-compartmental PK analysis of total
MPA was performed. Median time to myeloid and platelet engraft-
ment was 18 and 31 d, respectively. KM probability of Grade II-
IV acute GVHD (aGVHD) and extensive chronic GVHD
